Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NEO-201 |
| Synonyms | |
| Therapy Description |
NEO-201 is a monoclonal antibody that binds to tumor antigens, potentially including CEACAM family members, which may result in enhanced anti-tumor antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity (PMID: 29354121, PMID: 32637350). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NEO-201 | NEO 201|NEO201|h16C3 | NEO-201 is a monoclonal antibody that binds to tumor antigens, potentially including CEACAM family members, which may result in enhanced anti-tumor antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity (PMID: 29354121, PMID: 32637350). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03476681 | Phase I | NEO-201 | QUILT-3.017: Study of NEO-201 in Solid Tumors | Recruiting | USA | 0 |